SULF-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SULF-10 (SULF-10).
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
| Metabolism | Primarily renal excretion as unchanged drug; hepatic metabolism is minimal. |
| Excretion | Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15% |
| Half-life | Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment |
| Protein binding | Protein binding: 20-50% (primarily to albumin) |
| Volume of Distribution | Volume of distribution: 0.2-0.4 L/kg (low, indicating limited tissue distribution) |
| Bioavailability | Topical ophthalmic: minimal systemic absorption (<5%); oral: not applicable for this formulation |
| Onset of Action | Topical ophthalmic: within 30 minutes; oral: 2-4 hours (not a typical route for SULF-10) |
| Duration of Action | Topical ophthalmic: 4-6 hours; systemic absorption can prolong effects if applied to large areas |
| Molecular Weight | 250.27 |
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific renal dose adjustment recommended for topical ophthalmic use; systemic absorption is minimal. |
| Liver impairment | No specific hepatic dose adjustment recommended for topical ophthalmic use; systemic absorption is minimal. |
| Pediatric use | Safety and efficacy in pediatric patients not established; use same dosing as adults when prescribed, but consider age-appropriate supervision. |
| Geriatric use | No specific geriatric dose adjustment recommended for topical ophthalmic use; use with caution if concurrent renal or hepatic impairment, but systemic absorption is minimal. |
| 1st trimester | Avoid during first trimester; sulfonamides are associated with increased risk of congenital malformations and kernicterus risk later in pregnancy. |
| 2nd trimester | Use only if clearly needed; potential for neonatal jaundice and kernicterus due to bilirubin displacement. |
| 3rd trimester | Contraindicated near term (after 36 weeks) due to high risk of kernicterus in the newborn. |
Clinical note
Comprehensive clinical and safety monograph for SULF-10 (SULF-10).
| Placental transfer | Sulfonamides readily cross the placenta, achieving fetal serum concentrations of 50-100% of maternal levels. Competes with bilirubin for albumin binding, increasing risk of kernicterus. |
| Breastfeeding | Small amounts excreted into breast milk. In healthy, full-term infants with normal bilirubin levels, risk is low; however, avoid in premature infants or those with hyperbilirubinemia or G6PD deficiency due to potential for hemolysis and kernicterus. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to sulfonamidesPorphyriaSevere hepatic or renal impairmentNear term pregnancy (after 36 weeks)Infants less than 2 months of age (except for congenital toxoplasmosis)G6PD deficiency (relative; absolute in acute hemolytic episodes)
| Precautions | Hypersensitivity reactions including Stevens-Johnson syndrome; photosensitization; overgrowth of nonsusceptible organisms including fungi; prolonged use may result in corneal toxicity. |
| Food/Dietary | No known food interactions. Maintain adequate hydration. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) – caution advised; avoid in high-risk infants. |
| Teratogenic Risk | SULF-10 (Sulfacetamide 10%) is a topical sulfonamide antibiotic. Systemic absorption is minimal (<4%), and teratogenic risk is considered low. In first trimester, theoretical risk of neural tube defects due to folate antagonism exists if significant systemic absorption occurs; however, topical use generally poses negligible fetal exposure. No specific human data indicate increased malformations. In second and third trimesters, risk of kernicterus in neonates due to bilirubin displacement is theoretical but unlikely with topical use. Overall, classified as FDA Pregnancy Category C. |
| Fetal Monitoring | No specific monitoring required for topical use. If used on large areas or compromised skin, monitor for signs of sulfonamide toxicity (rash, urticaria, Stevens-Johnson syndrome, agranulocytosis). In pregnancy, monitor fetal growth and development with routine ultrasound if prolonged use. |
| Fertility Effects | No known adverse effects on fertility based on available data. Systemic absorption minimal, unlikely to impact reproductive function. |
| Sulfacetamide sodium 10% ophthalmic solution. For external use only. Avoid contact with soft contact lenses. Discard solution if it becomes dark or discolored. Use cautiously in patients with sulfonamide allergy. Concurrent use with silver-containing preparations may cause precipitation. |
| Patient Advice | Wash hands before each use. · Do not touch the dropper tip to any surface. · Apply the prescribed number of drops into the affected eye(s). · Do not wear contact lenses during treatment. · Discard the solution if it changes color or becomes cloudy. · Report any signs of allergic reaction (rash, itching, swelling). · Complete the full course of therapy as prescribed. |